Elevance Health, Inc. ELV is using a disciplined capital allocation strategy to balance shareholder returns with long-term business expansion. The company continues to invest in growth initiatives while returning excess cash through dividends and share repurchases. This balanced approach supports financial flexibility and positions ELV to navigate an evolving healthcare landscape without sacrificing future earnings potential.
The company's capital allocation is supported by robust cash generation. In the first quarter of 2026, ELV generated $4.3 billion in operating cash flow, up sharply from $1 billion a year ago, and expects full-year operating cash flow to be at least $5.5 billion. During the quarter, it returned around $1.5 billion to shareholders through $376 million in dividends and $1.1 billion in share repurchases. With $5.6 billion remaining under its share repurchase authorization as of March 31, 2026, the company retains significant flexibility to continue rewarding shareholders.
Additionally, ELV is directing capital toward businesses with attractive long-term growth prospects. The company continues to expand Carelon's capabilities across pharmacy, behavioral health, home-based care and value-based care while scaling AI to improve member engagement, reduce administrative costs and strengthen care management. These investments are expected to improve operating efficiency and diversify earnings beyond the traditional health insurance business.
Strong cash generation gives ELV the flexibility to fund growth initiatives while maintaining shareholder returns. Its ROIC of 8.3% exceeds the industry average of 6.6%. If the company continues executing this balanced strategy, its disciplined use of capital could support sustainable earnings growth and create lasting shareholder value.
How Are Competitors Faring?
Some of ELV’s competitors in the medical space are UnitedHealth Group Incorporated UNH and Humana Inc. HUM.
UnitedHealth generates solid cash from operations and returns value to investors via share repurchases and dividend payouts. In the first quarter of 2026, cash flows from operations were $8.9 billion, up 63.3% year over year. During the quarter, UNH paid dividends worth $2 billion.
Humana's strong financial position, supported by solid cash reserves and robust cash flows, has enabled it to return capital to shareholders. HUM generated net cash from operations of $1.3 billion in the first quarter of 2026, up nearly fourfold year over year. It repurchased shares worth $107 million in the first quarter of 2026 and paid dividends of $107 million.
Elevance Health’s Price Performance, Valuation & Estimates
Shares of ELV have risen 19.9% in the year-to-date period against the industry’s fall of 0.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, Elevance Health trades at a forward price-to-earnings ratio of 15, below the industry average of 16.38. ELV carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $26.86 per share, implying an 11.3% drop from the year-ago period.
Image Source: Zacks Investment Research
ELV stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Elevance Health, Inc. (ELV): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Humana Inc. (HUM): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).